You are here: Welcome » Robby Nieuwlaat

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Both sides next revision
robby_nieuwlaat [2022/06/14 19:43]
liam [Funding] 		robby_nieuwlaat [2022/06/14 20:38] (current)
liam [Funding]
Line 36: Line 36:
  
 Nieuwlaat is a member of the [[OMERACT]]-Adherence group, studying outcomes in [[rheumatology]]. He has co-authored publications funded by a 2018 [[Arthritis Australia]] project grant (major funder), and a private research grant provided by Professor [[Stephen Hall]].((Kelly, A., Tong, A., Tymms, K., March, L., Craig, J. C., De Vera, M., Evans, V., Hassett, G., Toupin-April, K., van den Bemt, B., Teixeira-Pinto, A., Alten, R., Bartlett, S. J., Campbell, W., Dawson, T., Gill, M., Hebing, R., Meara, A., Nieuwlaat, R., & Shaw, Y. (2018). //Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.// Trials, 19(1). https://doi.org/10.1186/s13063-018-2565-z)) Nieuwlaat is a member of the [[OMERACT]]-Adherence group, studying outcomes in [[rheumatology]]. He has co-authored publications funded by a 2018 [[Arthritis Australia]] project grant (major funder), and a private research grant provided by Professor [[Stephen Hall]].((Kelly, A., Tong, A., Tymms, K., March, L., Craig, J. C., De Vera, M., Evans, V., Hassett, G., Toupin-April, K., van den Bemt, B., Teixeira-Pinto, A., Alten, R., Bartlett, S. J., Campbell, W., Dawson, T., Gill, M., Hebing, R., Meara, A., Nieuwlaat, R., & Shaw, Y. (2018). //Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol.// Trials, 19(1). https://doi.org/10.1186/s13063-018-2565-z))
 +
 +==== Canadian Stroke Prevention Intervention Network ====
 +
 +Nieuwlaat is a Principal Investigator for the Knowledge Translation Program at the [[Canadian Stroke Prevention Intervention Network]].((//Robby Nieuwlaat.// (2014). Canadian Stroke Prevention Intervention Network. https://archive.ph/YcMI6))
  
 ==== INGUIDE ==== ==== INGUIDE ====
Line 52: Line 56:
  
 Yet further research has been funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[Eucomed]], [[University of Basel]], and [[Marche Polytechnic University]].((Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). //Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey.// EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205)) ((Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). //Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.// Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011)) ((Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). //Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.// Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793)) Yet further research has been funded by [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Sanofi]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[Eucomed]], [[University of Basel]], and [[Marche Polytechnic University]].((Guerra, F., Brambatti, M., Nieuwlaat, R., Marcucci, M., Dudink, E., Crijns, H. J. G. M., Matassini, M. V., & Capucci, A. (2017). //Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey.// EP Europace, 19(12), 1922–1929. https://doi.org/10.1093/europace/eux205)) ((Allemann, S. S., Nieuwlaat, R., Navarro, T., Haynes, B., Hersberger, K. E., & Arnet, I. (2017). //Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.// Journal of Clinical Epidemiology, 91, 70–79. https://doi.org/10.1016/j.jclinepi.2017.07.011)) ((Paquette, M., Riou França, L., Teutsch, C., Diener, H.-C., Lu, S., Dubner, S. J., Ma, C. S., Rothman, K. J., Zint, K., Halperin, J. L., Huisman, M. V., Lip, G. Y. H., & Nieuwlaat, R. (2017). //Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation.// Journal of the American College of Cardiology, 70(13), 1573–1583. https://doi.org/10.1016/j.jacc.2017.07.793))
 +
 +==== COVID-19 ====
 +
 +Nieuwlaat was lead author on a paper discussing [[antimicrobial resistance]] and [[COVID-19]] sponsored by the [[World Health Organization]].((Nieuwlaat, R., Mbuagbaw, L., Mertz, D., Burrows, L., Bowdish, D. M. E., Moja, L., Wright, G. D., & Schünemann, H. J. (2020). //COVID-19 and antimicrobial resistance: parallel and interacting health emergencies.// Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa773))
Back to top